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We describe how a gender specialist team managed the case of a disorder of sex development in a preterm infant where deﬁnitive
diagnosis and gender assignment were delayed due to complications of prematurity, anemia, and severe intrauterine growth
restriction.
1.Introduction
Disorders of sex development (DSD) represent a class of
congenital conditions in which there is atypical development
of the chromosomal, gonadal, or anatomical sex. Current
recommendations suggest that a multidisciplinary team be
used in the management of DSDs, ensuring that families
receive information in a timely, coordinated, and consistent
fashion [1]. Members of the team include, at a minimum,
pediatric endocrinologists, behavioral specialists, pediatric
urologists, geneticists, and, in some cases, neonatologists,
nurses, and social work staﬀ [2]. Under ideal conditions,
the behavioral specialist is a psychiatrist or psychologist with
experience providing support to families facing the unique
circumstances as well as medical and psychosocial decisions
associated with DSDs. Here, we describe an unusual case
of DSD complicated by prematurity and severe intrauterine
growth restriction (IUGR), which limited the ability to
completecomprehensivediagnostictesting.Wedescribehow
thisteamapproachtomanaginggenderassignmentoccurred
in concert with the medical issues related to prematurity.
2.CaseReport
This 0.617kg (-3SD) infant was born at 29 2/7 weeks to
a 28-year-old G1P0 mother. At 18 weeks gestation, parents
were informed that the infant was female based on results
of a prenatal ultrasound. Amniocentesis performed later in
the pregnancy revealed a 46, XY karyotype. The parents
presumed that the initial ultrasound results were incorrect
and were expecting a son. In the delivery room, genital
appearancewasdiscrepantwiththekaryotypicsex.Thephal-
lic structure was 4mm in length (full-term female normal
4.0 ± 1.24mm) [3, 4]. Labia majora were fused posteriorly
with no signs of hyperpigmentation or scrotalization. Labia
minora were absent, and gonads were not palpable. Introital
exam revealed a urethral opening at the base of the phallic
structure and a dimple consistent with a vaginal opening
anterior to the fusion of the labia majora. The anal opening
was normally placed. Pelvic ultrasound revealed no uterus
and bilateral gonadal structures consistent with testes above
the inguinal ring. The infant was transferred to the neonatal
intensive care unit for medical management of prematurity,2 Case Reports in Medicine
respiratory distress syndrome, and anemia. No gender was
assigned, and all staﬀ was instructed to refer to the infant as
“baby” or “infant.”
Labs drawn on day 1 of life were as follows: repeat kary-
otype 46, XY, testosterone 239ng/dL (normal 37–198ng/dL,
premature infant male; Kaleida Health Laboratory, Buﬀalo,
NY) and 17-hydroxyprogesterone 122ng/dL (normal 124–
841, premature infant 26–28 weeks, day 4; Esoterix, Raritan,
NJ). Additional labs to aid in the establishment of the DSD
were not obtained because of the infant’s low hematocrit
and small blood volume. Anatomical studies including
vesicoureterogramweredeferredduetosevereIUGR.Weekly
testosterone levels were drawn to identify the expected
postnatal rise in testicular testosterone at which time the
plan was to obtain testosterone/dihydrotestosterone levels to
address the diagnostic possibility of 5α-reductase deﬁciency.
This strategy was devised by the team to maximize the
likelihood of making a diagnosis at the time of testosterone
surge while limiting blood draws. On day 38 of life, the
infant developed presumed sepsis and expired. At the time
of death, no gender had been assigned, and further testing to
evaluate for 5α-reductase deﬁciency could not be performed
as testosterone levels remained <20ng/dL.
2.1. Clinical Case Management. On day one of life, the pedi-
atric endocrinologist met with the parents and advised that
gender assignment would be deferred while the diagnostic
evaluation was pursued. The parents were informed that
their child would be referred to as “baby” or “infant” until
gender was assigned. In addition, they were told that a
psychologist experienced in helping families and children
born with these conditions would be contacted immediately
and would meet with them. On day 2 of life, the psychologist
met with the parents for the purpose of (1) reinforcing
the recommendations of the medical team, (2) describing
typical development of the sexual-reproductive system and
how theirbabywasdiﬀerent,(3) agreeing to serve as a liaison
between the family and the medical team, and (4) assuring
them that if they decided on a gender diﬀerent from the
team’s recommendation that this would not compromise
their child’s care. The parents were engaged as an integral
partofthedecision-makingteam.Theparentsrequestedthat
all information relevant to gender assignment be given to




the information previously discussed and presented a
detailed description of the DSD diagnoses under consid-
eration. The parents were informed of the tests necessary
to discriminate between diagnoses and the reasons that the
team was unable to obtain all of the needed blood for testing.
They were informed that a stepwise approach to diagnostic
testing would be needed because of their child’s medical
condition. The parents agreed to delay gender assignment,
with the team keeping open the possibility of either a male or
female gender assignment.
Prior to the third session, the psychologist organized
a meeting with the medical team to discuss the parents’
requests, review the general status of the infant, and discuss
strategies to establish the DSD diagnosis. In addition to the
psychologist, the team members at this meeting included
theneonatologist,pediatricendocrinologist,andurologist.A
systematic and stepwise approach towards diagnostic testing
was developed taking into consideration that biochemical
testing was limited by the infant’s size and hemodynamic
status. Session three took place on day 17 of life and
includedtheparents,psychologist,pediatricendocrinologist,
and neonatologist. The family was briefed as to the medical
status and concerns that the neonatologist had related to
their infant, which included persistent anemia, hypotension,
and respiratory distress. The parents were interested in
clarifying the DSD diagnosis; understandably, at this stage
in the infant’s admission, the parents were focused primarily
on the medical condition of their child. The pediatric
endocrinologist discussed the most likely DSD diagnoses
(androgen insensitivity syndrome versus 5α-reductase deﬁ-
ciency) based on the physical exam ﬁndings and biochemical
studies to date. The endocrine testing necessary to aid
in the DSD diagnosis was reviewed. The parents elected
to pursue biochemical testing for 5α-reductase deﬁciency
while delaying genetic testing for androgen insensitivity
syndrome.
The ﬁnal meeting occurred shortly after the infant’s
death. The parents met with the psychologist, pediatric
endocrinologist, and neonatologist. The purpose was to
ﬁnalize the gender assignment by giving the baby a name
and to review the preliminary autopsy report. Additional
genetic testing was described that might clarify the DSD
diagnosis and aid in describing future risk for the family.
The family elected to assign a male gender to their child,
indicating that this decision was based on the initial
karyotype. They consented to further postmortem genetic
testing to address the DSD. While no speciﬁc queries were
made, it was the impression of the multidisciplinary team
that the parents were satisﬁed with the team’s handling
of this case. Mutational analysis performed to evaluate for
androgen insensitivity syndrome demonstrated that there
was no disease-associated mutation identiﬁed in exons 1–8
of the androgen receptor gene (GeneDx, Gaithersburg, MD).
Interestingly, although the family consented to the testing,
when they were contacted to review the results, they elected
not to pursue further counseling.
3. Discussion
Disorders of sex development (DSD) are a class of congenital
conditions involving anomalies of the sex chromosomes,
gonads, reproductive system, and genitalia. In certain DSD
diagnoses, the external genitalia are phenotypically incon-
gruouswiththegeneticsex.Insuchcases,genderassignment
management is best handled by a team of experts [2]. The
DSD presented here is consistent with an undervirilized 46,
XY individual. The broad diﬀerential diagnosis in this cat-
egory include rare causes of congenital adrenal hyperplasia
(such as StAR mutations, 17-hydroxysteroid dehydrogenase
mutations, 3β-hydroxysteroid dehydrogenase mutations),Case Reports in Medicine 3
androgen insensitivity syndrome (complete or partial), 5α-
reductase deﬁciency, ovotesticular DSD, gonadal dysgenesis,
and single gene mutations related to testicular development
(SRY,ST1,SF1)[2].However,itisrecognizedthatinasmany
as 50% cases of 46, XY DSD, no deﬁnitive diagnosis is made,
with30%ofthosehavingacodiagnosisofprematurity/IUGR
[5]. Even amongst individuals with an established clinical
diagnosis, the genetic and biochemical milieu is complex.
In fact, in a study of individuals diagnosed clinically with
either complete (CAIS) or partial androgen insensitivity
(PAIS), androgen receptor (AR) binding was normal in
7% and 64% of CAIS and PAIS patients, respectively, and
AR gene sequencing was normal in 17% (CAIS) and 77%
(PAIS) patients for whom genetic mutational analysis was
performed[6].Inaddition,ARbindingwasnormalin3of69
individuals forwhomexon screeningof theAR generevealed
am u t a t i o n[ 6]. Based on the clinical presentation of our
case, there was a high likelihood that a deﬁnitive diagnosis
would not be established. However, in order to provide the
family with the most complete information regarding long-
term outcomes with respect to gender assignment, as well
as risk to future children, the team pursued the biochemical
and genetic testing necessary to establish a diagnosis for the
family.
In the presented case, the karyotype, elevated testos-
terone level at birth, and presence of intra-abdominal testes
are consistent with male sex; however, the limited virilization
of the external genitalia virilization brings this assignment
into question. In fact, if the prenatal karyotype had not
been performed, this infant may not have been recognized
as having ambiguous genitalia and may have been assigned
femalegender.Genderassignmentisdependentonanumber
of factors including the diagnosis, the appearance of the
genitalia, options for surgical intervention, potential for
f e r t i l i t y ,f a m i l yo u t l o o k ,a sw e l la sl o n g - t e r mt r e a t m e n t ,a n d
outcome-based evidence regarding satisfaction with gen-
der assignment within diﬀerent DSD diagnoses [2]. It was
reported previously that individuals diagnosed with 46, XY
CAIS established an adult female gender identity [7]. How-
ever, 3 recently reported cases of 46, XY CAIS individuals
initially assigned as females self-changed gender to male
[8–11]. These cases highlight the unanswered questions
regarding the role of intrauterine brain androgenization and
development of gender identity, particularly since eﬀects of
prenatal and postnatal androgens are presumed to be absent
in those with CAIS. Individuals with PAIS are dissatisﬁed
with their gender assignment 25% of the time, regardless
of the initial assignment either male or female [12]. A
majorityofindividualswith5α-reductasedeﬁciencyassigned
female gender at birth transition to the male gender after
puberty, and all those assigned male gender at birth live as
males[13].Theoutcomeevidencerelatedtosatisfactionwith
gender assignment for other 46, XY DSDs is limited by small
patient numbers and diﬃculties with long-term followup.
In our case, diagnosis of DSD was signiﬁcantly hindered by
the infant’s prematurity, extreme IUGR, and hemodynamic
status.Astepwisediagnosticapproachwastakentominimize
the risk of compromising the infant’s clinical status, while, at
the same time, striving to arrive at a diagnosis that would aid
the family in assigning gender [14].
4. Conclusion
We present a case in which management was carried out by a
multidisciplinary team consisting of pediatric endocrinolo-
gists, neonatologists, a pediatric urologist, a geneticist, and
a psychologist specializing in the management of DSD.
The psychologist served as the team leader coordinating
communication between the parents and the medical profes-
sionals. The team provides the family with a comprehensive
explanation of normal and abnormal sexual diﬀerentiation
which becomes a template upon which they can understand
the DSD diagnosis and arrive at a decision regarding
gender assignment. In addition, when available, scientiﬁcally
validated outcome data is shared with the family regarding
speciﬁc diagnoses [2].
In most cases, an infant born with a DSD is considered
a medical “emergency”; every attempt is made to arrive at
a medical diagnosis in a timely fashion. A lack of diagnosis
is perceived as anxiety provoking for families and caregivers
when faced with an infant for whom gender assignment is
unclear. Based on our experience, we would argue that when
information related to patient care is relayed in a consistent
fashion, this anxiety may be alleviated. In our case, the
decision to assign gender was deferred for over 5 weeks, with
the ﬁnal decision (male) only being made by the parents
upon the infant’s untimely death.
This case teaches us an important lesson about the man-
agement of disorders of sex development by demonstrating
that, with support and education, gender assignments can
be delayed while diagnostic workup is being pursued. We
believe that this team-based strategy can be employed in
other complicated medical cases in which a diagnosis or
treatment regimen must be deferred. Given that the most
recent consensus statement encourages the team approach
as the standard of care for management of disorders of sex
development [2], randomized studies to address whether
parental anxiety is minimized by this method are unlikely to
be feasible. Validated questionnaires to address the concerns
of families related to the process of education, counseling,
diagnostic testing, and decision making will be an important
componenttotestoursuccessinthisﬁeld.Datagleanedfrom
clinical trials assessing parental stress and developmental
stage at which children are diagnosed with disorder of sex
development may guide the development of such question-
naires in the future [15].
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